AgTech AI Council

82% of next-gen in vivo CAR-T therapies are being developed in China—driven not by data volume, but by fast-track clinical pathways. What if AgTech AI could adopt the same model? The key isn’t more data—it’s faster validation. This insight comes from a new Nature article detailing China’s dominance in immune therapy trials: https://www.nature.com/articles/d41586-026-03004-3?error=cookies_not_supported&code=3f8bc1fb-7a3b-4193-b084-2d20337bd28b. How can we apply China’s investigator-initiated trial (IIT) framework to accelerate AI-driven agtech field testing? Let’s discuss the regulatory speed vs. data quality tradeoff in real-world AgTech AI deployment. Source: https://www.nature.com/articles/d41586-026-03004-3?error=cookies_not_supported&code=3f8bc1fb-7a3b-4193-b084-2d20337bd28b View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request.